Welcome to our dedicated page for TriSalus Life Sciences SEC filings (Ticker: TLSIW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TriSalus Life Sciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TriSalus Life Sciences's regulatory disclosures and financial reporting.
TriSalus Life Sciences, Inc. Chief Financial Officer David Patience reported a routine tax-related share withholding. The company withheld 14,650 shares of common stock at $4.46 per share to cover tax obligations arising from the vesting of previously granted restricted stock units. Following this transaction, Patience directly holds 261,107 shares of TriSalus common stock.
TriSalus Life Sciences, Inc. Chief Financial Officer David Patience reported a routine tax-related share withholding. The company withheld 14,650 shares of common stock at $4.46 per share to cover tax obligations arising from the vesting of previously granted restricted stock units. Following this transaction, Patience directly holds 261,107 shares of TriSalus common stock.
TriSalus Life Sciences CEO Mary T. Szela reported an acquisition of 3,990 shares of common stock. These shares were obtained at $3.87 per share through the company’s Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Following this grant, she directly holds 1,077,683 TriSalus shares.
TriSalus Life Sciences CEO Mary T. Szela reported an acquisition of 3,990 shares of common stock. These shares were obtained at $3.87 per share through the company’s Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Following this grant, she directly holds 1,077,683 TriSalus shares.
TriSalus Life Sciences, Inc. Chief Commercial Officer Richard Marshak acquired 561 shares of common stock at $3.8700 per share. The shares were obtained through the company’s Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Following this award, he directly holds 128,319 shares.
TriSalus Life Sciences, Inc. Chief Commercial Officer Richard Marshak acquired 561 shares of common stock at $3.8700 per share. The shares were obtained through the company’s Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Following this award, he directly holds 128,319 shares.
TriSalus Life Sciences, Inc. Chief Medical Officer Richard Henry received new equity compensation in the form of restricted stock units and stock options. He was granted 60,000 shares of common stock as restricted stock units, which will vest in four equal annual installments starting on June 29, 2027, assuming continued service. He also received an employee stock option for 120,000 shares of common stock at an exercise price of $4.74 per share, vesting over four years with one-fourth vesting on June 29, 2027 and the remainder monthly thereafter. Following these grants, he directly holds 90,000 shares of common stock and 253,000 stock options.
TriSalus Life Sciences, Inc. Chief Medical Officer Richard Henry received new equity compensation in the form of restricted stock units and stock options. He was granted 60,000 shares of common stock as restricted stock units, which will vest in four equal annual installments starting on June 29, 2027, assuming continued service. He also received an employee stock option for 120,000 shares of common stock at an exercise price of $4.74 per share, vesting over four years with one-fourth vesting on June 29, 2027 and the remainder monthly thereafter. Following these grants, he directly holds 90,000 shares of common stock and 253,000 stock options.
TriSalus Life Sciences, Inc. disclosed the initial equity holdings of its new Chief Medical Officer, Marshall Richard Henry, as he became an executive officer effective June 29, 2026. The filing shows direct ownership of 30,000 shares of common stock, acquired before his appointment.
Henry also holds several employee stock options giving rights to purchase additional common shares. These include options linked to 60,000, 48,000, and 25,000 underlying common shares at exercise prices of $5.55, $4.96, and $4.01 per share, expiring between 2034 and 2035. Footnotes describe time-based vesting schedules for both restricted stock units and these option grants, contingent on his continued service with the company.
TriSalus Life Sciences, Inc. disclosed the initial equity holdings of its new Chief Medical Officer, Marshall Richard Henry, as he became an executive officer effective June 29, 2026. The filing shows direct ownership of 30,000 shares of common stock, acquired before his appointment.
Henry also holds several employee stock options giving rights to purchase additional common shares. These include options linked to 60,000, 48,000, and 25,000 underlying common shares at exercise prices of $5.55, $4.96, and $4.01 per share, expiring between 2034 and 2035. Footnotes describe time-based vesting schedules for both restricted stock units and these option grants, contingent on his continued service with the company.
TriSalus Life Sciences disclosed beneficial ownership for James J. Pallotta. The amendment to Schedule 13G/A shows Mr. Pallotta beneficially owns 3,188,711 shares, equal to 5.2% of common stock based on May 8, 2026, and that this total includes 114,268 shares underlying warrants exercisable into common stock. The filing lists the issuer address as 6272 W. 91st Ave., Westminster, CO 80031 and is signed by James J. Pallotta on May 20, 2026.
TriSalus Life Sciences disclosed beneficial ownership for James J. Pallotta. The amendment to Schedule 13G/A shows Mr. Pallotta beneficially owns 3,188,711 shares, equal to 5.2% of common stock based on May 8, 2026, and that this total includes 114,268 shares underlying warrants exercisable into common stock. The filing lists the issuer address as 6272 W. 91st Ave., Westminster, CO 80031 and is signed by James J. Pallotta on May 20, 2026.
TriSalus Life Sciences, Inc. Chief Commercial Officer Richard Marshak reported a sale of 543 shares of common stock at $2.67 per share. According to the footnote, these shares were sold solely to satisfy tax withholding obligations from the vesting of previously granted restricted stock units and do not represent a discretionary sale. After this transaction, Marshak directly holds 125,101 shares of common stock.
TriSalus Life Sciences, Inc. Chief Commercial Officer Richard Marshak reported a sale of 543 shares of common stock at $2.67 per share. According to the footnote, these shares were sold solely to satisfy tax withholding obligations from the vesting of previously granted restricted stock units and do not represent a discretionary sale. After this transaction, Marshak directly holds 125,101 shares of common stock.
TriSalus Life Sciences director Mats Wahlstrom bought additional common stock in the open market. He acquired 60,000 shares at a weighted average price of $2.53 per share, with individual trades priced between $2.52 and $2.56. Following this purchase, he holds 147,555 shares directly.
Wahlstrom is also associated with significant indirect holdings. HW Investment Partners, LLC holds 1,370,028 shares, where he is a managing member and he disclaims beneficial ownership beyond his economic interest. Leonard Capital LLC holds 1,444,447 shares, over which he and his spouse share voting and investment discretion.
TriSalus Life Sciences director Mats Wahlstrom bought additional common stock in the open market. He acquired 60,000 shares at a weighted average price of $2.53 per share, with individual trades priced between $2.52 and $2.56. Following this purchase, he holds 147,555 shares directly.
Wahlstrom is also associated with significant indirect holdings. HW Investment Partners, LLC holds 1,370,028 shares, where he is a managing member and he disclaims beneficial ownership beyond his economic interest. Leonard Capital LLC holds 1,444,447 shares, over which he and his spouse share voting and investment discretion.
TriSalus Life Sciences director Michael P. Stansky reported significant open-market buying of the company’s common stock. On May 15, 2026, an entity he manages, Skyview Investments LLC, purchased 200,000 shares at a weighted average price of $2.50 per share, bringing its holdings to 399,698 shares held indirectly. On the same date, he also purchased 410,000 shares directly at a weighted average price of $2.50 per share, increasing his direct ownership to 1,240,722 shares. The filing notes that each block was acquired through multiple trades within stated price ranges.
TriSalus Life Sciences director Michael P. Stansky reported significant open-market buying of the company’s common stock. On May 15, 2026, an entity he manages, Skyview Investments LLC, purchased 200,000 shares at a weighted average price of $2.50 per share, bringing its holdings to 399,698 shares held indirectly. On the same date, he also purchased 410,000 shares directly at a weighted average price of $2.50 per share, increasing his direct ownership to 1,240,722 shares. The filing notes that each block was acquired through multiple trades within stated price ranges.
TriSalus Life Sciences CEO Mary T. Szela bought 39,682 shares of common stock in an open-market purchase at a weighted average price of $2.59 per share. After this transaction, she directly holds 1,065,215 common shares.
A footnote explains these purchases are matchable under Section 16(b) against earlier sales that were made solely to cover tax withholding on vesting restricted stock units. The filing states she paid $27,573.70 to the company, equal to the profit from this short-swing transaction.
TriSalus Life Sciences CEO Mary T. Szela bought 39,682 shares of common stock in an open-market purchase at a weighted average price of $2.59 per share. After this transaction, she directly holds 1,065,215 common shares.
A footnote explains these purchases are matchable under Section 16(b) against earlier sales that were made solely to cover tax withholding on vesting restricted stock units. The filing states she paid $27,573.70 to the company, equal to the profit from this short-swing transaction.